Last reviewed · How we verify
Hyperprolactinemia
Approved treatments
- Dostinex · Par Pharmaceutical, Inc.
- Parlodel · Esjay Pharma
- Dostinex · Pfizer Japan Inc.
- Bromocriptin · University Hospital, Bonn
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Hyperprolactinemia patent landscape — cliff calendar, originator estates, attackable patents
- Hyperprolactinemia treatment landscape brief
- Hyperprolactinemia treatment updates RSS
Frequently asked questions about Hyperprolactinemia
What drugs treat Hyperprolactinemia?
Tracked treatments include Dostinex, Parlodel, Bromocriptin.
What is the treatment for Hyperprolactinemia?
Standard treatment for Hyperprolactinemia includes Dostinex, Parlodel, Bromocriptin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Hyperprolactinemia patent cliff · Hyperprolactinemia CI report
- Treatment: Dostinex · Par Pharmaceutical, Inc.
- Treatment: Parlodel · Esjay Pharma
- Treatment: Dostinex · Pfizer Japan Inc.
- Treatment: Bromocriptin · University Hospital, Bonn
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing